WASHINGTON, DC, March 4, 2015 – The Alliance for Regenerative Medicine (ARM) today announced additional discussion leaders for its upcoming fifth annual Advanced Therapies Summit next Thursday, March 12, 2015 in Paris, France. The event this year will feature five expert-led interactive roundtables with representatives from more than 20 of the field’s leading companies and organizations.
This one-day meeting will bring together top executives and clinical researchers from the advanced therapies community across Europe and the U.S. for collaborative roundtable sessions aimed at broadening understanding of the sector and how to continue its growth and success. In addition to offering attendees the opportunity to be active in the program’s discussions, the Summit will also provide extensive networking opportunities with industry CEOs, senior executives and translational experts.
“This region has experienced steady growth over the past few years, “ said Michael Hunt, chief financial officer of ReNeuron. “From financings and deals to the number of clinical trials underway, the EU is a leading force for advanced therapies worldwide.”
2015 Featured Discussions:
State of the Advanced Therapies Industry Remarks
Edward Lanphier, Chairman, Alliance for Regenerative Medicine; President and CEO, Sangamo BioSciences
Roundtable I: Cell Therapy Commercialization
Discussion Leaders:
Eduardo Bravo, CEO, TiGenix
Olav Hellebo, CEO, ReNeuron
Georges Rawadi, Ph.D., VP Business Development, Cardio3 BioSciences
Timothy Schroeder, CEO, CTI Clinical Trial & Consulting Services
Kunihiko Suzuki, Vice Chairman, Forum for Innovative Regenerative Medicine (FIRM); Member of the Board & Chief Business Officer, MEDINET
Roundtable II: Gene Therapy in Europe and the U.S.
Discussion Leaders:
Karen Aiach, President & CEO, Lysogene
Jean-Philippe Combal, Pharm. D., Ph.D., COO, GenSight Biologics
Peter Nolan, Chief Business Officer, Oxford BioMedica
Frédéric Revah, Ph.D., CEO, Genethon
Roundtable III: Big Pharma's Evolving Advanced Therapies Outlook
Discussion Leaders:
Stewart Abbot, Ph.D., Executive Director, Integrative Research, Celgene Cellular Therapeutics
Nicolas Koebel, Global Commercial Lead, Rare Diseases, GlaxoSmithKline
Deborah Van Riet, Director, Future Therapeutics & Technologies, Integrated Science & Technology, AbbVie
Roundtable IV: The Role of Europe’s Major Cell & Gene Therapy Research Institutions in Enabling Effective Clinical & Commercial Translation
Discussion Leaders:
Matthew Durdy, Chief Business Officer, Cell Therapy Catapult
Annamaria Merico, Business Development Office, Fondazione Telethon
Thomas Tradler, Ph.D., Head of Business Development & Patent Management, Fraunhofer Institute for Cell Therapy and Immunology
Marc Turner, MB, Ch.B., Ph.D., Professor, Cellular Therapy, University of Edinburgh MRC Centre for Regenerative Medicine; Medical Director, Scottish National Blood Transfusion Service (SNBTS)
Closing Discussion: ARM's Agenda for Europe in 2015
Discussion Leaders:
Michael Hunt, Co-Chair, European Section, Alliance for Regenerative Medicine; Chief Financial Officer, ReNeuron
Alexander Vos, Co-Chair, European Section, Alliance for Regenerative Medicine; CEO, PharmaCell
The event will be held at the Paris Marriott Rive Gauche Hotel & Conference Center located at 17 Boulevard Saint Jacques in Paris, France. Registration is open – to learn more and to register, please visit ARM’s event page.
For members of the media interested in attending, please contact Lyndsey Scull (lscull@alliancerm.org) for information regarding complimentary press registration.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 200 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
# # #
